Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

Inclusion Criteria: 1. men and women 18 years or older 2. Elevated LDL-C on current lipid lowering therapy and; prior atherosclerotic cardiovascular disease (CVD) event or evidence of CVD or without CVD but at high risk for CVD based on American Heart Association/American College of Cardiology (AHA/ACC) CVD risk calculator, or aged 40 years and older with diabetes and moderate- to high-intensity statin, or pre-treatment LDL-C 190 mg/dL or greater or heterozygous familial hypercholesterolemia (HeFH) 3. patients who met original entry criteria in, and completed, the double-blind, placebo-controlled 16-week Phase 2 study (LIB003-002) Exclusion Criteria: 1. patients who did not who complete the double-blind, placebo-controlled 16-week Phase 2 study (LIB003-002) 2. \<18 years of age 3. pregnant or women of childbearing potential not using acceptable birth control